NOD2 Agonist-Stimulated Stem Cells for Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive and anti-inflammatory drugs have significant side effects and high costs, limiting their effectiveness in treating immune disorders and inflammatory diseases, and there is a need for more efficient methods to regulate immune responses.
Innovation Solution
A pharmaceutical composition comprising stem cells expressing NOD2, cultured with a NOD2 agonist, which promotes the secretion of PGE2 and TGF-β1, providing an immunosuppressive and anti-inflammatory effect without side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive and anti-inflammatory drugs are used, then immune responses are suppressed, but significant side effects and high costs occur
Solution Approach 1:
The patent uses stem cells as an intermediary biological agent to mediate immunosuppression. Instead of directly administering chemical drugs that cause side effects, stem cells are cultured with NOD2 agonists to induce them to secrete PGE2 and TGF-β1, which then act as natural mediators to suppress immune responses. This intermediary approach allows immunosuppression to occur through physiological mechanisms rather than direct chemical intervention, thereby reducing harmful side effects.
Solution Approach 2:
The patent changes the parameters of stem cells by culturing them with specific concentrations of NOD2 agonists (such as MDP at 1-100 μg/mL) for specific time periods. This parameter change induces the stem cells to differentiate or activate specific pathways that lead to increased secretion of immunosuppressive mediators PGE2 and TGF-β1. By controlling cultivation parameters, the patent optimizes the immunosuppressive effect while avoiding the side effects associated with conventional drug therapy.
2Reliability
If conventional immunosuppressive drugs are used, then immune responses are suppressed, but high treatment costs occur
Solution Approach 1:
The patent employs stem cells that can be cultured in vitro using relatively inexpensive media and NOD2 agonists. These stem cells serve as a disposable therapeutic product that can be manufactured at lower costs compared to conventional immunosuppressive drugs. The stem cells are cultured, activated with NOD2 agonists to produce immunosuppressive mediators, and then administered. This approach replaces expensive long-term drug therapy with a more cost-effective cellular therapy that achieves similar or better clinical outcomes.
Solution Approach 2:
The stem cells possess inherent immunosuppressive capabilities that are enhanced through cultivation with NOD2 agonists. Rather than requiring continuous external administration of expensive drugs, the stem cells themselves serve as a self-sustaining therapeutic agent. Once administered, they can continuously secrete PGE2 and TGF-β1 to maintain immunosuppression, reducing the need for repeated expensive drug administrations and lowering overall treatment costs.
3Reliability
If NOD2 agonist is used to stimulate immune response, then immune response is enhanced, but excessive inflammation may occur
Solution Approach 1:
The patent applies partial action by using controlled concentrations of NOD2 agonists during stem cell cultivation rather than direct administration to patients. The NOD2 agonist is used in vitro at optimized concentrations to induce stem cells to secrete immunosuppressive mediators, but not so much as to cause excessive inflammation in vivo. This partial application of the agonist effect during cultivation achieves the desired immunomodulation without the harmful effects of excessive inflammation that would occur with direct high-dose agonist administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses immune and inflammatory responses, offering a cost-effective alternative for treating autoimmune diseases and inflammatory conditions like Crohn's disease, rheumatoid arthritis, and atopic dermatitis, with minimal side effects.
Implementation Method 1
NOD2 is known to play a vital role in an innate immune response by recognizing PGN moiety from the cell walls of most bacteria. The most widely known agonist (ligand) among the ones that are recognized by NOD2 is a muramyl dipeptide (MDP)
Implementation Method 2
NOD2 induces an innate immune response of antibacterial activity acting as a defense protein in the body. PGE2 has been suggested as a strong candidate for new immunosuppressive modulator, as it functions to suppress release of cytokines such as interleukin-1 beta and TNF alpha which are produced by macrophage
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 1e~2
AI summary
The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expressing Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE2 or TGF-β1 comprising the step of culturing NOD2-expressing stem cells in culture medium with a NOD2 agonist, a graft comprising stem cells expressing NOD2 and the NOD2 agonist, a method for preparing the graft, a composite comprising stem cells expressing NOD2 and the NOD2 agonist, and a culture generated by culturing the NOD2-expressing stem cells with a NOD2 agonist.